Structure of Human Cytochrome P450 2D6 solved by GlaxoSmithKline with the use of Fludigm Technology

21-Mar-2006

The TOPAZ® system for protein crystallization was instrumental in helping GlaxoSmithKline (GSK) solve the structure of cytochrome P450 2D6, an enzyme important in the metabolism of a wide variety of drugs. TOPAZ crystallization chips were used to identify positive conditions for crystallization and subsequently to grow P450 2D6 crystals sufficiently large and well ordered for structural analysis. The research was conducted by the GSK Discovery Research Group in Harlow, UK, and the findings are presented in the Journal of Biological Chemistry.

For this protein target, conventional microplate crystallization trials failed to yield crystals suitable for an X-ray crystal structure determination, according to Paul Rowland, Investigator, Structural Sciences at GSK. Consequently, the team turned to TOPAZ preparative chips to further explore crystallisation conditions and to scale up those which appeared promising. In the paper Rowland et al. describe the procedure whereby crystals were grown and harvested from the TOPAZ chips and then used to solve the protein structure.

The P450 2D6 structure is a milestone in ongoing work to determine the structures of various bound substrates and inhibitors related to ligand recognition and specificity in human cytochrome systems. A relatively large number of genetic polymorphisms have been described for 2D6, some of which are markers for rapid, or conversely, very poor metabolism. A deeper understanding of these polymorphisms as facilitated by 3-dimensional structural considerations may lead to safer, more efficacious drugs. The publication of the P450 2D6 structure attests to the value of a long-standing collaboration between GSK and Fluidigm to integrate TOPAZ technology into the drug discovery process.

GlaxoSmithKline plc (GSK)

Recommend news PDF version / Print

Share on

Facts, background information, dossiers
  • GSK
  • crystallization
  • metabolism
  • GlaxoSmithKline
  • scale-up
  • protein structure
  • protein crystallization
  • inhibitors
  • Fluidigm
  • Enzyme
  • Determination
  • chemistry
More about GSK
  • News

    Researchers locate geographic origins from DNA

    A study published in Nature by an international team that included Cornell researchers describes the use of DNA to predict the geographic origins of individuals from a sample of Europeans, often within a few hundred kilometers of where they were born. "What we found is that within Europe, ... more

    Thermo Fisher Scientific Extends Reach in India with Addition of Leading Laboratory Chemicals Supplier

    Thermo Fisher Scientific Inc. announced it has entered into an agreement to acquire Qualigens Fine Chemicals, a division of GlaxoSmithKline Pharmaceuticals Ltd. (GSK India) based in Mumbai. Qualigens is India's largest laboratory chemical manufacturer and supplier, serving customers in a va ... more

    Out of REACH

    Europe's proposed new chemicals legislation, REACH, could disrupt the supply of important medicines. David Vosvenieks, REACH issue manager at AstraZeneca (AZ), told Chemistry & Industry that two companies supplying intermediates required for two AZ drugs - one of them an anticancer therapy ... more

More about Fluidigm
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE